Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Leases (2020 - 2025)

Arcutis Biotherapeutics has reported Operating Leases over the past 6 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $5.3 million for Q4 2025, up 105.54% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 105.54% YoY), and the annual figure for FY2025 was $5.3 million, up 105.54%.
  • Operating Leases for Q4 2025 was $5.3 million at Arcutis Biotherapeutics, roughly flat from $5.3 million in the prior quarter.
  • Over the last five years, Operating Leases for ARQT hit a ceiling of $5.3 million in Q3 2025 and a floor of $2.1 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $4.4 million (2022), compared with a mean of $4.0 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 6058.54% in 2021 and later tumbled 35.31% in 2024.
  • Arcutis Biotherapeutics' Operating Leases stood at $4.8 million in 2021, then fell by 13.76% to $4.1 million in 2022, then dropped by 17.85% to $3.4 million in 2023, then decreased by 24.25% to $2.6 million in 2024, then surged by 105.54% to $5.3 million in 2025.
  • The last three reported values for Operating Leases were $5.3 million (Q4 2025), $5.3 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.